All Companies


Acceleron Pharma Inc [XLRN] US$2,282 MM MCap
The com­pa­nies have mul­ti­ple Ph2 and Ph3 trials on­go­ing for chron­ic ane­mia in ad­di­tio­n­al pa­tient pop­u­la­tions of MDS and be­ta-tha­lassemia, as well as myelo­fi­bro­sis. The com­pany ex­pects to re­port to­p­line re­sults from Ph2 clin­i­cal trials in PAH (so­tater­cept) and CMT (ACE-083) in Q1 2020. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$138 MM MCap
Re­cent­ly launched DSU­VIA; rev-gen­er­at­ing in Q1. Plans to re­sub­mit Za­lvi­so NDA in US by YE [more in­for­ma­tion]
Achilles Therapeutics
cNeT (clo­n­al neoanti­gen) pro­cess builds on TILs, com­bined with abil­i­ty to iden­ti­fy pt-spe­cif­ic clo­n­al neoanti­gens and gen­er­ate per­so­n­al­ized T-cell ther­a­pies. Sep19 GBP100 mil­lion Se­ries B w/ RA, Syn­co­na, For­bion, In­vus, Per­cep­tive + Red­mile. [more in­for­ma­tion]
Adverum Biotechnologies [ADVM] US$582 MM MCap
Oc­u­lar / rare dis­ease gene thx. AD­VM-022 in P1 OP­TIC study in wAMD. 24-wk da­ta from co­hort 1 (6 pts) re­port­ed in Sep (0 res­cue in­jec­tions). 52-wk da­ta from co­hort 1 and 24-wk da­ta from co­hort 2 exp 1H20. [more in­for­ma­tion]
Affibody
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. Lead can­di­date is an IL-17 with pos­i­tive Ph2 12wk da­ta in pso­ri­a­sis. Al­so has a Ph1 FcRn for b-cell au­toim­mune dis­eas­es part­nered with ALXN. Rev­enue gen­er­at­ing from ear­li­er li­censed as­sets. Backed by In­ves­tor AB. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$151 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) to en­ter a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. [more in­for­ma­tion]
Aileron Therapeutics, Inc. [ALRN] US$14 MM MCap
Clin­i­cal stage on­col­o­gy com­pany con­duct­ing 3 clin­i­cal trials for its lead can­di­date, AL­RN-6924, a first-in-class/best-in-class drug that tar­gets the p53 path­way. AL­RN-6924 is from the Sta­pled pep­tide plat­form and is the on­ly clin­i­cal drug can­di­date that binds equipo­tent­ly to both of the p53 sup­pres­sor pro­teins, MD­MX and MD­M2. [more in­for­ma­tion]
AM-Pharma B.V.
Treat­ing sep­sis as­so­ci­at­ed acute kid­ney in­jury (AKI) with pro­pri­e­tary re­com­bi­nant al­ka­line phos­pha­tase (re­cAP). Re­sults from Ph 2 trial in 300+ pts, de­mon­s­trat­ed rel­a­tive im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ing piv­o­tal Ph 3 in SA-AKI pa­tients in Q1 20 (P end­point: Day 28 all-cause mor­tal­i­ty). First in­ter­im anal­y­sis exp Q1 2021. [more in­for­ma­tion]
Amarin Corporation [AMRN] US$7,713 MM MCap
Com­mer­cial­iz­ing Vas­ce­pa, the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA. 2019 gui­dance of $380-420M, or 66-83% high­er y/y. [more in­for­ma­tion]
Antev
An­tev is a clin­i­cal stage spe­cial­i­ty phar­ma­ceu­ti­cal com­pany with a pri­mary fo­cus is on pros­tate can­cer and urol­o­gy with an in­ter­est in wo­m­en's health. The lead in­di­ca­tion is pros­tate can­cer, fol­lowed by be­nign pro­stat­ic hy­per­pla­sia (BPH), acute uri­nary re­ten­tion (AUR), uterine fi­broids and en­dometrio­sis. [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Aptorum Group [APM] US$456 MM MCap
Ap­to­rum is a phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to de­vel­op­ing and com­mer­cial­iz­ing a broad range of ther­a­peu­tic and di­ag­nos­tic tech­nolo­gies to tack­le un­met med­i­cal needs. Ap­to­rum is pur­su­ing ther­a­peu­tic and di­ag­nos­tic pro­jects in neu­rol­o­gy, in­fec­tious dis­eas­es, gas­troen­terol­o­gy, on­col­o­gy and other dis­ease ar­eas; [more in­for­ma­tion]
Arcellx
Cur­rent en­gi­neered im­mune cell ther­a­pies of­ten tar­get tu­mors through a mono-spe­cif­ic re­cep­tor that is con­sti­tu­tive­ly ex­pressed and ac­tive. In con­trast, Ar­cel­lx has de­vel­oped Anti­gen Re­cep­tor Com­plex T cells (ARC-T) that are read­i­ly si­lenced, ac­ti­vat­ed, and re­pro­grammed in vi­vo by ad­min­is­tra­tion of a tu­mor-tar­get­ing anti­gen pro­tein called a sparX. [more in­for­ma­tion]
AsclepiX Therapeutics
AX­T107 de­mon­s­trat­ed ef­fi­ca­cy and dura­bil­i­ty in rab­bit and mouse mod­els that is su­pe­ri­or to stan­dard of care Eye­lea. [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung in­jury, Ph 3 trial is on­go­ing. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$314 MM MCap
Tar­get­ing HBV w/ oral core in­hibi­tors - po­ten­tial to in­crease cure rates. Lead can­di­date 731 in Ph 2: +ive safe­ty and de­creas­es in cc­cD­NA pop with pts ex­pect­ed to be with­drawn from treat­ment in 2020 and fol­lowed for sus­tained vi­ral DNA sup­pres­sion off ther­a­py. [more in­for­ma­tion]
Avacta [AVCT:LN] £36 MM MCap
UK-based com­pany de­vel­op­ing pro­pri­e­tary next-gen anti­bodies called Af­fimers. Avac­ta is a new Trout client that is a bit un­der the ra­dar with limit­ed US-ex­po­sure to date. They are a bit small/ear­ly but we have been gett­ing in­ter­est so far on their ap­proach – sim­i­lar con­cept to Ab­l­ynx, part­n­er­ship with Mod­er­na, etc. Af­fimers are 10X small­er than tra­di­tio­n­al anti­bodies that are easy to for­mat, high­ly spe­cif­ic, easy to man­u­fac­ture, mul­ti­ple routes of ad­min­is­tra­tion, etc. – com­para­ble to Ab­l­ynx’s nan [more in­for­ma­tion]
AxoGen [AXGN] US$619 MM MCap
Da­m­age or tran­sec­tion to pe­ripher­al nerves. Q1 revs $23.3M, 35% growth YoY; exp 2019 rev bt $109-$114M [more in­for­ma­tion]
Bavarian Nordic A/S [BVNRY] US$791 MM MCap
Vaccines for in­fec­tious dis­eas­es and on­col­o­gy. [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$41 MM MCap
Molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­ables phar­ma­co­log­ic con­trol over cells for en­hanced ef­fi­ca­cy and safe­ty. Lead (reg­is­tra­tio­n­al EU) pro­gram: Ph2 for ri­vo-cel (al­pha/be­ta ad­d­back T-cell ther­a­py for post al­lo­gene­ic HSTC in non-ma­lig­nant and ma­lig­nant dis­eas­es). Pos­i­tive late in­ter­im anal­y­sis on ri­vo-cel exp at ASH 2018; [more in­for­ma­tion]
Bellus Health [BLU:CA] Can$445 MM MCap
BEL­LUS' lead prod­uct can­di­date, BLU-5937, is be­ing de­vel­oped for the treat­ment of chron­ic cough (Phase II an­nounced Ju­ly 2020) and chron­ic pru­ri­tus (Phase II planned to be­gin 1H20). [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr1,019 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$2,561 MM MCap
sub­mitt­ed NDAs for Zy­dis ODT (oral­ly dis­solv­ing tablet) and tablet for­mu­la­tions of rimege­pant in 2Q19. Up­com­ing mile­s­tones: 4Q19/1Q20: (1) Ph 3 to­p­line (pre­ven­tive mi­graine) (2) Ph 2/3 to­p­line (in­tra­nasal/acute treat­ment of mi­graine) (3) Ph 2/3 to­p­line (gen. anxi­e­ty di­s­or­der) (4) Ph 2/3 in­ter­im (Alzheimer's); 1Q20: (5) Ph 2/3 to­p­line (OCD) [more in­for­ma­tion]
BioXcel Therapeutics, Inc. [BTAI] US$69 MM MCap
Our two most ad­vanced clin­i­cal de­vel­op­ment pro­grams are BX­CL501, a sublin­gual thin film for­mu­la­tion of dexmede­to­mi­dine de­signed for acute treat­ment of ag­i­ta­tion re­sult­ing from neu­ro­log­i­cal and psychi­a­tric di­s­or­ders, and BX­CL701, an im­muno-on­col­o­gy agent de­signed for treat­ment of a rare form of pros­tate can­cer and for treat­ment of pan­cre­at­ic can­cer. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$312 MM MCap
an­nounced $2.7m rev­enue in 3Q. NM­PA re­view in progress for ZE­VALIN® and MAR­QI­BO® (in-li­censed from Spec­trum). 3Q: li­censed oc­treotide for dev/dist in Chi­na (SOC for acrome­ga­ly). 2Q: acq'd ex­clu­sive WW rights to com­mer­cial­ize an­ti-CD19 T-cell ther­a­py (CNC­T19) in Chi­na + ex­clu­sive WW rights to nov­el an­ti-CD38 mAb (CID-103). [more in­for­ma­tion]
Catabasis Pharmaceuticals Inc [CATB] US$61 MM MCap
Rare dis­ease pipe­line, with lead prod­uct Edasa­lonex­ent in Ph 3 trial in Duchenne mus­cu­lar dys­tro­phy re­gard­less of mu­ta­tion type. North Star Am­bu­la­to­ry As­sess­ment as the pri­mary end­point based on Phase 2 re­sults and FDA in­put. Top-line re­sults ex­pect­ed in 2020. [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$484 MM MCap
Fir­dapse ap­proved 11/18, Q1 sales of $12m: 380 ac­tive LEMS pa­tients on ther­a­py (a/o May 9) [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] US$347 MM MCap
Vali­dates CB­MG's in-house cell man­u­fac­tur­ing ca­pa­bil­i­ties de­vel­oped in part­n­er­ship with Gen­er­al Elec­tric and Ther­mo Fish­er. CB­MG's pro­pri­e­tary im­muno-on­col­o­gy pipe­line in­cludes BC­MA, CD22, TCR-T for HCC and TIL for the treat­ment of NS­CLC and other solid tu­mors. [more in­for­ma­tion]
CerSci Therapeutics
De­vel­op­ing a new gen­er­a­tion of non-opi­oid medicines to treat acute post-op­er­a­tive and chron­ic neu­ro­path­ic pain. Lead pro­gram in Phase 1, CT-044, tar­get­ing TR­PA1 chan­nels which are prone to hy­per-ac­ti­va­tion, known to trig­ger pain sen­sa­tions. [more in­for­ma­tion]
CureVac AG
Cure­vac is a pri­vate Ger­man com­pany with mR­NA plat­form, di­ver­si­fied pipe­line, and three lead pro­grams in ph1: CV8102 (vari­ous can­cer in­di­ca­tions), CV9202 (NS­CLC) and CV7202 (Ra­bies). Last fi­nanc­ing round done at over $1bn. Other com­pa­nies in the space: MR­NA, TBIO, BN­TX. [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$133 MM MCap
$100m revs in F18. Pi­oneer in molec­u­lar di­ag­nos­tics (Dx), lead­ing con­ver­gence of clin­i­cal lab­o­ra­to­ries, life sci­ences and IP through de­vt of unique Dx plat­form tech­nolo­gies pro­vid­ing nu­mer­ous ad­van­tages over pre­vi­ous stan­dards. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] US$104 MM MCap
ES­SA Phar­ma Inc is a pre­clin­i­cal stage phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of small molecule drugs for the treat­ment of cas­tra­tion-re­sis­tant pros­tate can­cer. [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$254 MM MCap
Se­cured $30M strate­g­ic in­vest­ment from PDL Bio­S­ciences (PDLI) in April 2019 for 6.7M shares at $4.50 (26% pre­mi­um to pri­or day close) and 25% war­rant cov­er­age. [more in­for­ma­tion]
Forbius
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
Genfit SA [GNFTF] US$613 MM MCap
$155m Mar 2019 US IPO; FDA BTD for Ela­fi­branor (4/19); (+) 36-mo DSMB rec for cont­in­u­a­tion of Ph 3 study in NASH; da­ta by YE [more in­for­ma­tion]
GenSight Biologics [SIGHT:PA] €31 MM MCap
Gene ther­a­py: reti­nal & CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Fil­ing for MAA exp Q1 2020 in EU and Q4 2020 in US. Op­to­ge­net­ic pro­gram and tar­get­ed dis­ease im­me­di­ate­ly trans­fer­able to dry AMD. Plat­form com­bines mono-ge­net­ic ther­a­py-based ap­proach w core tech­nol­o­gy plat­form and pro­pri­e­tary Mi­to­chon­drial Tar­get­ing Se­quence. [more in­for­ma­tion]
HaemaLogiX
I-O; nov­el tgts in Mul­ti­ple Myelo­ma. Kap­paMab (MM) Ph 2b, da­ta 1H20. Kap­paMab Car-T en­ter­ing clin­ic 2019. Kap­paMab & Lamb­daMab tar­get cell sur­face pro­teins KMA and LMA on ab­nor­mal plas­ma cells. Kap­paMab: com­plete & par­tial re­spons­es in Ph 1 & 2a. Kap­pa-mab Car-T en­ter­ing clin­ic 2019 [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$3,046 MM MCap
Chi-Med has a port­fo­lio of 9 drugs in clin­i­cal de­vel­op­ment from own dis­cov­ery en­gine in its In­no­va­tion plat­form and a cash gen­er­at­ing Com­mer­cial plat­form with 2,500+ sales reps. Glob­al col­lab­o­ra­tion with As­traZene­ca in two reg­is­tra­tion en­abling studies with savol­i­tinib in Ta­gris­so re­frac­to­ry lung can­cer that is MET+ and EGFRm+ (glob­al) and MET Ex­on 14 dele­tion NS­CLC (Chi­na). [more in­for­ma­tion]
I-Mab Biopharma
The com­pany built its strong pipe­line with strong in­ter­nal re­search sup­ple­ment­ed with ac­tive li­cens­ing from lead­ing glob­al bio­phar­ma part­n­ers such as best in class sg­p130 molecules from Fer­ring, unique CD38 mAb from Mor­phosys, and mul­ti­ple late stage molecules from Genexine. [more in­for­ma­tion]
Idera Pharmaceuticals, Inc. [IDRA] US$60 MM MCap
Lead can­di­date Til­so­toli­mod (TLR 9 ag­on­ist) used in comb w Ipi in PD1 re­frac­to­ry me­lano­ma pts. En­rolling ad­dl pts in Ph 2 ex­pan­sion and Phase 3 en­roll­ment ex­pect­ed to com­plete Q4 2019. Com­bo of ipi and Til­so­toli­mod ap­pears to ac­ti­vate im­mune re­sponse in pts who have ex­haust­ed all op­tions, e.g. PD1/CPIs. Fast Track des for Til­so­toli­mod (Nov’17). [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
Mor­phaBond ER™ US com­mer­cial launch Nov 2017 (FDA-ap­proved, first sin­gle-en­ti­ty abuse de­ter­rent ER mor­phine prod­uct) and Rox­y­Bond™ (FDA ap­proved, first and on­ly IR abuse-de­ter­rent opi­oid prod­uct) both li­censed to Daiichi Sankyo, Inc. Nov­el ex­tend­ed and im­me­di­ate re­lease tech­nolo­gies en­able pain med­i­ca­tions with abuse de­ter­rent fea­tures, ad­dress­ing the Opi­oid epi­dem­ic. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$2,802 MM MCap
Late-stage cell ther­a­py com­pany uti­l­iz­ing pro­pri­e­tary au­tol­o­gous tu­mor in­fil­trat­ing lym­pho­cytes (TILs) to at­tack solid tu­mors. The com­pany is con­duct­ing piv­o­tal stage trials in me­tastat­ic me­lano­ma and ad­vanced cer­vi­cal can­cer with BLAs ex­pect­ed 2020. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$508 MM MCap
Plat­form of ROCK in­hibi­tors. ROCK2 in­hibi­tor in reg­is­tra­tion trial cGVHD; en­roll­ment com­ple­tion exp 2H19; ini­tial anal­y­sis exp YE. Ph 2 ini­ti­a­tion in scle­ro­der­ma exp in 2019. [more in­for­ma­tion]
Kiadis Pharma N.V. [KIADF] US$49 MM MCap
Ad­dress­ing blood can­cers: NK-cell (K-NK) and T-cell (ATIR101) plat­forms ad­min­is­tered as ad­junc­tive I-O on top of HSCT. ATIR101: Al­lo-de­plet­ed T-cell ther­a­py for HSCT re­duces risk of GVHD while re­tain­ing im­mu­ni­ty vs tu­mor & in­fec­tion. Up­com­ing mile­s­tones: 2020 -- K-NK trial ini­ti­a­tions (r/r AML & HSCT), 2021 -- ATIR101 Ph 3 en­roll­ment comp & in­ter­im da­ta; K-NK in­ter­im da­ta (HSCT) [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) is fo­cused on in­nate im­mu­ni­ty and im­munol­o­gy. Signed 2 large ear­ly stage part­ner­ing deals in 2018 - $520M deal with Pfiz­er for its small molecule RIG-I im­munother­a­py and a $360M+ deal with Ge­nen­tech for KCP506, a pre­clin­i­cal, non-opi­oid for chron­ic pain. LHF-535 in Ph 1 for Las­sa Fev­er (fund­ed by Well­come Trust, eli­gi­ble for PRV). [more in­for­ma­tion]
Landos Biopharma
Based on ex­ten­sive pre­clin­i­cal studies, Lan­dos has vali­dat­ed a unique mech­anism of ac­tion in­volv­ing LAN­CL2 that ex­erts po­tent an­ti-in­flam­ma­to­ry ef­fects with an out­s­tand­ing safe­ty pro­file. [more in­for­ma­tion]
Lineage Cell Therapeutics [LCTX] US$119 MM MCap
Cur­rent­ly has 3 clin­i­cal pro­grams: (i) OpRe­gen®, a reti­nal pig­ment epithe­li­um tran­s­plant ther­a­py in Ph 1/2a de­vel­op­ment for dry AMD; ii) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py in Ph 1/2a de­vel­op­ment for acute spi­nal cord in­juries; and (iii) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in Ph 1 for NS­CLC. [more in­for­ma­tion]
Marker Therapeutics [MRKR] US$129 MM MCap
A clin­i­cal-stage im­muno-on­col­o­gy com­pany with the po­ten­tial to sig­ni­f­i­cant­ly dis­rupt the cur­rent cell ther­a­py land­s­cape. Mark­er's cur­rent Mul­ti­TAA cell ther­a­py is look­ing to ini­ti­ate a Phase II study in AML in 2020. [more in­for­ma­tion]
Medivir AB [MVIR B:ST] SKr936 MM MCap
Biri­na­pant/Keytru­da® com­bo in Ph 2 MSS CRC with in­ter­im da­ta in 4Q19; MIV-818 in Ph 1 in liv­er can­cer, ear­ly POC Ph 1a da­ta in 2Q19 / Phase 1b to start in 4Q19. Remeti­no­s­tat in Ph 2 ISS study for BCC, pos­i­tive in­ter­im da­ta in 2Q19. BD/li­cenc­ing op­por­tu­ni­ties: Ph 3 ready MIV-711 for OA and Ph 3 ready remeti­no­s­tat for CT­CL. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPAR&gam­ma; ag­on­ist, MIN-102, in Piv­o­tal Ph 2/3 for X-linked ALD and Ph 2 Frie­drich’s Ataxia; da­ta for both ex­pect­ed by end of 2020. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] US$79 MM MCap
Re­cent­ly went public through merg­er with Aqui­nox. De­sign­ing de no­vo pro­tein im­munother­a­pies us­ing com­pu­ta­tio­n­al meth­ods. Lead pro­gram NL-201: cy­tokine mimet­ic (ne­oleukin) to ac­ti­vate im­mune cells for can­cer; first de no­vo pro­tein ther­a­peu­tic ev­er cre­at­ed. [more in­for­ma­tion]
NeuroRx
The Com­pany re­port­ed Phase 2 ef­fi­ca­cy and safe­ty da­ta for NRX-011 in De­cem­ber 2018, suggest­ing po­ten­tial for NRX-101 in main­tain­ing re­mis­sion from sev­er­al bipo­lar de­pres­sion with acute sui­ci­dal idea­tion fol­low­ing an ini­tial sta­bi­l­iza­tion with ke­tamine. [more in­for­ma­tion]
NexImmune, Inc.
Anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Mul­ti­ple IND fil­ings exp H1'19. [more in­for­ma­tion]
Oncimmune [ONC:LN] £32 MM MCap
Oncim­mune's pro­pri­e­tary plat­form is un­der­pinned by rapid bio­mark­er dis­cov­ery and a com­pre­hen­sive im­muno­genic pro­tein li­brary of over 8,000 anti­genic pro­teins. [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr6,699 MM MCap
Melflufen (Yga­lo): alky­lat­ing pep­tide se­lec­tive­ly tar­gets MM; su­pe­ri­or ef­fi­ca­cy vs. SOC. In­ter­im da­ta at EHA (2018) from on­go­ing Ph2 study in late stage r/r MM showed ORR of ~32%. [more in­for­ma­tion]
PAION AG [PAIOF] US$144 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
Rev­enue gen­er­at­ing with marine-de­rived and nov­el MoA on­col­o­gy prod­ucts. Zep­syre (lur­binecte­din), op­ti­mized ana­log of Yon­delis, re­port­ed pos­i­tive Ph 2 re­sults - com­pany will file its NDA un­der ac­cel­er­at­ed ap­pro­val for lur­binecte­din monother­a­py for the treat­ment of re­lapsed SCLC dur­ing Q4, 2019, with po­ten­tial ap­pro­val and US launch in 2020. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €760 MM MCap
De­vel­op­ment pipe­line in­cludes RU­CON­EST in new ver­sions (LCM), new li­cense from No­var­tis of late stage drug Le­ni­olis­ib for APDS (ul­tra-rare im­mun­od­e­fi­cien­cy con­di­tion), rhC1INH for new larg­er in­di­ca­tions in­clud­ing con­tract-in­duced nephro­pa­thy, pre-eclamp­sia and AKI, re­com­bi­nant al­pha-Glu­cosi­dase for Pompe dis­ease [more in­for­ma­tion]
Pharvaris
Phar­varis is fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. POC was de­mon­s­trat­ed in a mon­key mod­el and it’s ap­pli­ca­ble to all pa­tients in HAE. [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr1,252 MM MCap
Pho­to­cure is a rev­enue-gen­er­at­ing com­mer­cial stage com­pany fo­cused on urol­o­gy. The com­pany re­cent­ly an­nounced FDA ap­pro­val of sN­DA to ex­tend in­di­ca­tion to in­clude Flex­i­ble Cy­to­s­copes for on­go­ing surveil­lance of blad­der can­cer. The com­pany is fo­cused on grow­ing Cysview rev­enues in the US. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$190 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Pliant has de­vel­oped a port­fo­lio of ful­ly-owned de­vel­op­ment can­di­dates fo­cused on in­hibit­ing the TGFb path­way through in­te­grin in­hi­bi­tion. The com­pany’s lead prod­uct can­di­date, PLN-74809 is an oral small-molecule du­al se­lec­tive in­hibi­tor of &al­pha;vß6 and &al­pha;vß1 in­te­grins that is be­ing de­vel­oped in idio­path­ic pul­mo­nary fi­bro­sis (IPF), and pri­mary scle­ros­ing cholan­gi­tis (PSC). [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$294 MM MCap
PTG-300 in­jectable hep­cidin mimet­ic Ph 2 be­ta-tha­lassemia ini­tial re­sults ex­pect­ed 4Q19; PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis to be­gin ear­ly 2020; PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist Ph 2 Crohn’s dis­ease study on­go­ing. [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$291 MM MCap
Med-tech; bio­elec­tric medicine plat­form com­pany bring­ing to mar­ket its pro­pri­e­tary CellFX Sys­tem plat­form har­ness­ing its unique Nano-Pulse Sti­m­u­la­tion tech­nol­o­gy. Com­pany filed for 510(k) clear­ance with the FDA dur­ing 2019 based on strong clin­i­cal da­ta from mul­ti­ple ap­pli­ca­tion clin­i­cal studies in its first ap­pli­ca­tion area, aes­thet­ic der­ma­tol­o­gy. Clear­ance is ex­pect­ed dur­ing the fourth quar­ter of 2019 with com­mer­cial­iza­tion fol­low­ing prompt­ly. [more in­for­ma­tion]
R2 Dermatology
Di­rec­tor of the Well­man Cen­ter of Pho­tomedicine at Mas­sachusetts Gen­er­al Hos­pi­tal in Bos­ton, a teach­ing af­fili­ate of Har­vard Med­i­cal School; of the Cu­ta­neous Bi­ol­o­gy Re­search Cen­ter in the De­part­ment of Der­ma­tol­o­gy at Mas­sachusetts Gen­er­al Hos­pi­tal; [more in­for­ma­tion]
Regent Pacific [575:HK]
Re­gent Pa­cif­ic is a di­ver­si­fied in­vest­ment group based in Hong Kong cur­rent­ly hold­ing vari­ous cor­po­rate and strate­g­ic in­vest­ments fo­cus­ing on the health­care, well­ness and life sci­ences sec­tors. The Group has a strong track re­cord of in­vest­ments and has re­turned ap­prox­i­mate­ly US$298 mil­lion to share­hold­ers in the 21 years of fi­nan­cial re­port­ing since its ini­tial public of­fer­ing. [more in­for­ma­tion]
Resolve Therapeutics
An im­muno-ther­a­peu­tics com­pany de­vel­op­ing first-in-class, safe, tar­get­ed ther­a­pies for un­derserved au­toim­mune dis­eas­es. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni) and sm molecule se­lec­tive CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors in Ph 1b (ini­ti­at­ed in H1'19) [more in­for­ma­tion]
Savara Inc. [SVRA] US$29 MM MCap
Or­phan lung dis­ease; Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion [more in­for­ma­tion]
Selecta Biosciences, Inc. [SELB] US$66 MM MCap
Im­mune tol­er­ance plat­form (Imm­TOR) de­vel­oped in com­bo with rare dis­ease ther­a­pies. SEL-212 (chron­ic re­frac­to­ry gout) in COM­PARE Ph 2 trial vs KRYS­TEXXA®; in­ter­im da­ta 1Q20. Gene tx pipe­line in pre­clin de­vel­op­ment with Imm­TOR where re-dos­ing re­quire. Ask­Bio and Spark col­labs. [more in­for­ma­tion]
Sol-Gel Technologies Ltd. [SLGL] US$155 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). 2 P3 read­outs in 2019: Rosacea: mid-2019; Acne: YE [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc.
Son­net's in­ter­leukin-based can­di­date has been shown to en­hance pK (up to 10 fold) and im­prove tu­mor de­liv­ery with an in­crease in in vi­vo ef­fi­ca­cy (30 fold) as de­mon­s­trat­ed in a mice tu­mor mod­el. The Son­net plat­form de-risks the use of in­ter­leukins by great­ly ex­tend­ing their in vi­vo half-life, while al­so im­prov­ing their spe­ci­fic­i­ty to tu­mor tis­sue. [more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$474 MM MCap
EL­ZON­RIS, tar­get­ed ther­a­py di­rect­ed to IL-3 re­cep­tor (CD123, ap­proved for BPDC; SL-801 an oral small molecule re­v­ersi­ble in­hibi­tor of XPO1 in Ph 1 trial; and SL-701 an im­munother­a­peu­tic that com­plet­ed Ph 2 trial in pts w/2nd line GBM [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
STRATEC SE [SBS:FF] €810 MM MCap
Au­to­ma­tion sys­tems and soft­ware for di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS (BioMerieux) and AD­VIA (Sie­mens). Rev gen­er­at­ing and pro­f­itable; growth drivers in­cl prod­uct launch­es/ramp-ups, new tests; de­mo­graph­ics and out­sourc­ing in IVD in­dus­try. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$85 MM MCap
Rare dis­eas­es; Keveyis for PPP 2019 rev­enue gui­dance of $18-20M; Re­cor­lev 2nd Phase 3 top-line re­sults 1Q 2020; NDA sub­mis­sion exp 3Q 2020 [more in­for­ma­tion]
Sutro Biopharma [STRO] US$250 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. STRO-001 for mul­ti­ple myelo­ma and lym­pho­mas is in Ph 1 and ex­pects ini­tial safe­ty da­ta in mid-2019. IND sub­mis­sion for STRO-002 for ovarian and en­dome­trial can­cer in Q4 2018 with the ini­ti­a­tion of a Ph 1 trial planned for ear­ly 2019. [more in­for­ma­tion]
Syneos Health [SYNH] US$5,238 MM MCap
Sy­neos Health® is an end-to-end, ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions com­pany that works dif­fer­ent­ly. At Sy­neos Health, all the dis­ci­p­lines in­volved in bring­ing new ther­a­pies to mar­ket, from clin­i­cal to com­mer­cial, work to­gether to cre­ate cus­tomer suc­cess. Our unique Bio­phar­ma­ceu­ti­cal Ac­cel­er­a­tion Mod­el de­liv­ers val­ue across the small to mid-size to large cus­tomer cont­in­u­um. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr319 MM MCap
Strong re­sults from Part 1 (ON­COS-102/Keytru­da com­bo) trial in an­ti-PD1 re­frac­to­ry me­lano­ma: 33% ORR in 9 pts: 1 CR, 2 PRs; in all 9 pts. Up­com­ing mile­s­tones: ran­domized da­ta, Ph 1b/2 (me­sothe­lio­ma, n=31) w/che­mo: Jan 2020; Ph 1, Part 2 da­ta (me­lano­ma comb w/Keytru­da, n=21): 1H2020; up­dates from col­lab part­n­ers in peri­toneal me­tas­ta­sis & pros­tate exp 2020 [more in­for­ma­tion]
Tessa Therapeutics
On­go­ing Ph III (na­sopha­ryn­geal can­cer), up­com­ing piv­o­tal Ph II (Hodgkin lym­pho­ma), and mul­ti­ple other clin­i­cal-stage pro­grams. GMP fa­cil­i­ty un­der con­struc­tion. Key col­lab­o­ra­tions: Bay­lor, Park­er Inst., St. Jude Chil­dren’s, and JV in Chi­na. [more in­for­ma­tion]
Vaccitech Limited
T cell im­munother­a­pies for in­fec­tious dis­eas­es (ID) and can­cer via CD8+ T cell in­duc­tion – spi­nout from Jen­n­er In­sti­tute. ChA­dOx (prime) and MVA (boost) pipe­line in­clud­ing piv­o­tal Ph2b for flu pro­phy­lac­tic in Q1 2020 and Ph1/2 POC for HPV and HBV im­munother­a­pies by Q1 2021, two can­cer im­munother­a­py pro­grams (per­so­n­al­ized vaccine and MAGE-NYE­SO ther­a­peu­tics) en­ter­ing clin­ic in 2020. [more in­for­ma­tion]
Vericel Corporation [VCEL] US$829 MM MCap
Re­cord Q3 MA­CI and Epi­cel revs of $30.5m (vs $22.5m in 2018). 2019 rev­enue gui­dance for MA­CI® and Epi­cel® raised to $112 to $116m. Ex­pand­ed MA­CI sales­force. Nexo­Brid BLA fil­ing tar­get­ed for 1H 2020. [more in­for­ma­tion]
Verrica Pharmaceuticals [VRCA] US$385 MM MCap
is an in­no­va­tive clin­i­cal-stage med­i­cal der­ma­tol­o­gy com­pany com­mitt­ed to iden­ti­fy­ing, de­vel­op­ing, and com­mer­cial­iz­ing nov­el phar­ma­ceu­ti­cal prod­ucts for the treat­ment of skin dis­eas­es and con­di­tions with sig­ni­f­i­cant un­met needs. [more in­for­ma­tion]
Viela Bio [VIE] US$1,355 MM MCap
De­vel­op­ing nov­el ther­a­pies for wide range of au­toim­mune and se­vere in­flam­ma­to­ry dis­eas­es, fo­cus­ing on shared crit­i­cal bi­o­log­i­cal path­ways to tar­get un­der­ly­ing cause of dis­ease [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$93 MM MCap
June 2019 pos­i­tive da­ta for TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in pa­tients with T1D. Re­sults from the se­cond part of the Ph2 study ex­pect­ed Q1 2020.&nb­sp;Re­cent­ly an­nounced the first pa­tient has been screened for the Ph2 proof of con­cept study eval­u­at­ing the safe­ty and ef­fi­ca­cy of azeli­ra­gon in pa­tients with mild Alzheimer's dis­ease and Type 2 Di­a­betes. [more in­for­ma­tion]
Yisheng Biopharma
De­vl bio­ther­a­peu­tics for can­cers and in­fec­tious dis­ease. Prod­ucts in de­vt in­clude Ph 1 IO prod­uct tar­get­ing solid tu­mors Ph 3 PI­KA vaccine tar­get­ing hep B and ra­bies in­fec­tions. [more in­for­ma­tion]
Zentalis
In house de­vel­oped drug scaf­folds de­signed to yield best-in-class com­pounds in on­col­o­gy. Lead pro­grams are an oral SERD to be used in me­tastat­ic and ad­ju­vant sett­ings, cur­rent­ly in Ph 2, and a next-gen­er­a­tion DNA Da­m­aged Re­sponse (DDR) drug tar­get­ing WEE1 for solid tu­mors. Filed three INDs in its first four years with another three planned in the next two years. Found­ed in 2015. [more in­for­ma­tion]